Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2005-08-16
2005-08-16
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C514S025000, C514S033000, C514S034000
Reexamination Certificate
active
06929802
ABSTRACT:
This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of(a) evaluating the subject to determine if the subject has relapsed or refractory cancer;(b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
REFERENCES:
patent: 5811119 (1998-09-01), Mehta
patent: 5821254 (1998-10-01), Sporn
patent: 5874412 (1999-02-01), Priebe
patent: 5902604 (1999-05-01), Zou et al.
Acton et al., “Intensely potent morpholinyl anthracyclines,”J. Med Chem., 27:638-645. 1984.
Barbieri et al., “Chemical and biological characerization of 4′-iodo-4′ deoxydoxorubicin,”Cancer Res., 47:4001-4006, 1987.
Chaudhary and Roninson, “Induction of multidrug resistance in human cells by transient exposure to difference chemotherapeutic drugs,”J. Natl. Cancer Inst., 85:632-639, 1993.
Consoli et al., The novel anthracycline annamycin is not affected by p-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines,Blood, 88(2):633-644, 1996.
Dalton, “Overcoming the multidrug-resistant phenotype,”Principles and practice Oncology, 4thEd., 6:2655-2666, Philadelphia, 1993.
Den Boer et al., “Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia,”Leukemia, 11:1078-1085, 1997.
DeVita et al., “Principles of chemotherapy”,Principles and Practice of Oncology4thEd., Pholadelphia, 1993.
Gabizon et al., “Liposomes as in vivo carriers of adriamcycin: reduced cardiac uptake and preserved antitumor activity in mice”,Cancer Res., 42:4734-4739, 1982.
Ganapathi et al., “N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumors: cellular pharmacology and characterization of cross-resistance in vitro and in vivo,”Br. J. Cancer, 60:819-826, 1989.
Herman et al., Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation,:Cancer Res., 43:5427-5432, 1983.
Leith et al., “Correlation of multidrug resistance (MDRI) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR/efflux + and MDRI +/efflux cases,”Blood, 86:2329-2343, 1995.
Maria, “Phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice,”Leukemia, 11:1063-1066, 1997.
Mayhew et al., “Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin,”Cancer Drug Deliver, 1:43-57, 1983.
Moscow and Cowan, “Mutlidrug resistance,”J. Natl, Cancer Inst., 80:14-20.
Perez-Soler and Priebe, “Anthracycline antibodies with high lipsome entrapment; structural features and biological activity,”Cancer Res., 50:4260-4266, 1990.
Perez-Soler,Cancer Chemoth. Pharm., 34:109-118, 1994.
Rahman et al., “Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin li;osomes,”Cancer Res., 46:2295-2299, 1986.
Zou et al., Antitumor activity of free and liposome-entrapped annamycin, a lipohilic anthracycline antibiotic with non-cross-resistance properties, ABSTRACT,Cancer Res., 54:1479-1484, 1984.
Zou et al., “Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for liid membranes, entrapped in multilamellar vesicles,”Cancer Chemther. Pharmacol., 32:190-196, 1993.
Zou et al., “Quantitative analysis of the liphilic doxorubicin analog annamycin in plasma and tissue samples by reverse-phase chromatography,”J. Pharm. Sciences, 82:1151-1154, 1993.
Andreeff Michael
Estey Elihu H.
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Kishore Gollamudi S.
LandOfFree
Method of cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3440533